Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia
© 2024, Zhou, Ni, Liao et al..
Thrombocytopenia caused by long-term radiotherapy and chemotherapy exists in cancer treatment. Previous research demonstrates that 5-Hydroxtrayptamine (5-HT) and its receptors induce the formation of megakaryocytes (MKs) and platelets. However, the relationships between 5-HT1A receptor (5-HTR1A) and MKs is unclear so far. We screened and investigated the mechanism of vilazodone as a 5-HTR1A partial agonist in promoting MK differentiation and evaluated its therapeutic effect in thrombocytopenia. We employed a drug screening model based on machine learning (ML) to screen the megakaryocytopoiesis activity of Vilazodone (VLZ). The effects of VLZ on megakaryocytopoiesis were verified in HEL and Meg-01 cells. Tg (itga2b: eGFP) zebrafish was performed to analyze the alterations in thrombopoiesis. Moreover, we established a thrombocytopenia mice model to investigate how VLZ administration accelerates platelet recovery and function. We carried out network pharmacology, Western blot, and immunofluorescence to demonstrate the potential targets and pathway of VLZ. VLZ has been predicted to have a potential biological action. Meanwhile, VLZ administration promotes MK differentiation and thrombopoiesis in cells and zebrafish models. Progressive experiments showed that VLZ has a potential therapeutic effect on radiation-induced thrombocytopenia in vivo. The network pharmacology and associated mechanism study indicated that SRC and MAPK signaling are both involved in the processes of megakaryopoiesis facilitated by VLZ. Furthermore, the expression of 5-HTR1A during megakaryocyte differentiation is closely related to the activation of SRC and MAPK. Our findings demonstrated that the expression of 5-HTR1A on MK, VLZ could bind to the 5-HTR1A receptor and further regulate the SRC/MAPK signaling pathway to facilitate megakaryocyte differentiation and platelet production, which provides new insights into the alternative therapeutic options for thrombocytopenia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
eLife - 13(2024) vom: 04. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
112692-38-3 |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Electronic Dryad: 10.5061/dryad.7m0cfxq34 Citation Status MEDLINE |
|---|
| doi: |
10.7554/eLife.94765 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370632427 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370632427 | ||
| 003 | DE-627 | ||
| 005 | 20240408232948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7554/eLife.94765 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370632427 | ||
| 035 | |a (NLM)38573820 | ||
| 035 | |a (PII)RP94765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Activating SRC/MAPK signaling via 5-HT1A receptor contributes to the effect of vilazodone on improving thrombocytopenia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Dryad: 10.5061/dryad.7m0cfxq34 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024, Zhou, Ni, Liao et al. | ||
| 520 | |a Thrombocytopenia caused by long-term radiotherapy and chemotherapy exists in cancer treatment. Previous research demonstrates that 5-Hydroxtrayptamine (5-HT) and its receptors induce the formation of megakaryocytes (MKs) and platelets. However, the relationships between 5-HT1A receptor (5-HTR1A) and MKs is unclear so far. We screened and investigated the mechanism of vilazodone as a 5-HTR1A partial agonist in promoting MK differentiation and evaluated its therapeutic effect in thrombocytopenia. We employed a drug screening model based on machine learning (ML) to screen the megakaryocytopoiesis activity of Vilazodone (VLZ). The effects of VLZ on megakaryocytopoiesis were verified in HEL and Meg-01 cells. Tg (itga2b: eGFP) zebrafish was performed to analyze the alterations in thrombopoiesis. Moreover, we established a thrombocytopenia mice model to investigate how VLZ administration accelerates platelet recovery and function. We carried out network pharmacology, Western blot, and immunofluorescence to demonstrate the potential targets and pathway of VLZ. VLZ has been predicted to have a potential biological action. Meanwhile, VLZ administration promotes MK differentiation and thrombopoiesis in cells and zebrafish models. Progressive experiments showed that VLZ has a potential therapeutic effect on radiation-induced thrombocytopenia in vivo. The network pharmacology and associated mechanism study indicated that SRC and MAPK signaling are both involved in the processes of megakaryopoiesis facilitated by VLZ. Furthermore, the expression of 5-HTR1A during megakaryocyte differentiation is closely related to the activation of SRC and MAPK. Our findings demonstrated that the expression of 5-HTR1A on MK, VLZ could bind to the 5-HTR1A receptor and further regulate the SRC/MAPK signaling pathway to facilitate megakaryocyte differentiation and platelet production, which provides new insights into the alternative therapeutic options for thrombocytopenia | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-HT1A receptor | |
| 650 | 4 | |a medicine | |
| 650 | 4 | |a megakaryocyte | |
| 650 | 4 | |a mouse | |
| 650 | 4 | |a thrombocytopenia | |
| 650 | 4 | |a vilazodone | |
| 650 | 7 | |a Vilazodone Hydrochloride |2 NLM | |
| 650 | 7 | |a U8HTX2GK8J |2 NLM | |
| 650 | 7 | |a Receptor, Serotonin, 5-HT1A |2 NLM | |
| 650 | 7 | |a 112692-38-3 |2 NLM | |
| 700 | 1 | |a Ni, Chengyang |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Ruixue |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Xiaoqin |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Taian |e verfasserin |4 aut | |
| 700 | 1 | |a Ran, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xiaogang |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Dalian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Feihong |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Jiesi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jianming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t eLife |d 2012 |g 13(2024) vom: 04. Apr. |w (DE-627)NLM221831460 |x 2050-084X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g day:04 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7554/eLife.94765 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |b 04 |c 04 | ||